Dermatology News

Approximately 83% to 88% of Canadian patients with immune-mediated inflammatory disease have received two doses of a COVID-19 vaccine, compared with 78% of the general population, according to data published in The Journal of Rheumatology.

The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.

In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic.

Tenosynovitis detected through power Doppler ultrasound predicts rheumatoid and inflammatory arthritis development in patients with clinically suspect arthralgia, according to data published in Arthritis Research & Therapy.

The FDA has approved AbbVie’s risankizumab-rzaa for the treatment of adults with active psoriatic arthritis, expanding its initial indication from plaque psoriasis only.

A 2-week-old baby girl presented with a rash in the diaper area. She was born prematurely at 32 weeks’ gestation and was hospitalized in the NICU.

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

Approximately 61% of patients with rheumatoid arthritis or psoriatic arthritis who use methotrexate report side effects following weekly dosing, including fatigue and nausea, according to data published in Rheumatology and Therapy.

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

The FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe atopic dermatitis among patients aged 12 years and older, according to a press release.